- Home
- IIIV vs DAWN Comparison
IIIV vs DAWN Comparison
Compare IIIV & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IIIV
- DAWN
- Stock Information
- Founded
- IIIV 2012
- DAWN 2018
- Country
- IIIV United States
- DAWN United States
- Employees
- IIIV N/A
- DAWN N/A
- Industry
- IIIV EDP Services
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- IIIV Technology
- DAWN Health Care
- Exchange
- IIIV Nasdaq
- DAWN Nasdaq
- Market Cap
- IIIV 748.8M
- DAWN 624.8M
- IPO Year
- IIIV 2018
- DAWN 2021
- Fundamental
- Price
- IIIV $31.39
- DAWN $7.03
- Analyst Decision
- IIIV Buy
- DAWN Strong Buy
- Analyst Count
- IIIV 6
- DAWN 7
- Target Price
- IIIV $34.33
- DAWN $27.86
- AVG Volume (30 Days)
- IIIV 289.1K
- DAWN 2.1M
- Earning Date
- IIIV 08-07-2025
- DAWN 08-05-2025
- Dividend Yield
- IIIV N/A
- DAWN N/A
- EPS Growth
- IIIV N/A
- DAWN N/A
- EPS
- IIIV 5.56
- DAWN N/A
- Revenue
- IIIV $248,271,000.00
- DAWN $187,638,000.00
- Revenue This Year
- IIIV N/A
- DAWN $16.42
- Revenue Next Year
- IIIV $4.56
- DAWN $47.52
- P/E Ratio
- IIIV $7.62
- DAWN N/A
- Revenue Growth
- IIIV 25.08
- DAWN 2190.50
- 52 Week Low
- IIIV $20.42
- DAWN $5.64
- 52 Week High
- IIIV $33.44
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- IIIV 59.20
- DAWN 57.59
- Support Level
- IIIV $30.09
- DAWN $6.71
- Resistance Level
- IIIV $31.82
- DAWN $7.48
- Average True Range (ATR)
- IIIV 1.01
- DAWN 0.29
- MACD
- IIIV -0.07
- DAWN 0.09
- Stochastic Oscillator
- IIIV 62.18
- DAWN 72.73
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.